Patents by Inventor Tilman Lappchen

Tilman Lappchen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240371538
    Abstract: The present invention relates to a method for preparing a radioactive polymerizable solution and the solution per se. The solution is prepared by using a cationic radionuclide with a half-life >5 d that is dissolved in an aqueous solution. The radionuclide is extracted into an organic solvent or monomer solution by using a lipophilic ligand for forming a radioactive complex. The ligand is characterized by a ?2:1 ratio of carbon and/or silicon atoms to specific heteroatoms. If an organic solvent is used for extraction, the organic phase obtained is subsequently diluted in a monomer solution to obtain the radioactive polymerizable solution. The invention further relates to the use of said solution in a method for preparing a radioactive object such as a phantom for medical imaging and the object per se.
    Type: Application
    Filed: May 30, 2022
    Publication date: November 7, 2024
    Applicant: UNIVERSITÄT BERN
    Inventors: Michael HENTSCHEL, Tilman LÄPPCHEN, Lorenz Paul MEIER, George Amadeus PRENOSIL
  • Publication number: 20150147273
    Abstract: A method for determining whether compound 0118 is a candidate treatment for a patient includes processing, via a processor, image data of tissue of interest of a patient including a cancer to determine whether a radiolabeled analog of compound 0118 is present in the tissue of interest represented in the image data and generating a signal indicating that compound 0118 is a candidate treatment for the patient in response to the determining that the radiolabeled analog of compound 0118 is present in a predetermined amount in the tissue of interest represented in the image data, wherein the presence of the radiolabeled analog of compound 0118 in the tissue of interest indicates presence of a sub-type of cancer having a galectin-1 molecular target, which is a sub-type of treatable by compound 0118.
    Type: Application
    Filed: June 10, 2013
    Publication date: May 28, 2015
    Applicant: Koninklijke Philips N.V.
    Inventors: Tilman Lappchen, Holger Gruell, Marc Stefan Robillard, Johan Lub